Skip to main content
Toggle navigation
Login
Search
Home
Tweets by IDWeek 2023
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Daniel F. Sahm, PhD
VP Global Microbiology Services & Chief Scientific Officer
IHMA
Poster(s):
(2119)
In Vitro
Activity of Aztreonam-Avibactam Against Enterobacterales Isolated from Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2017-2021
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2127)
In vitro
Activities of Ceftaroline and Comparator Agents against Bacterial Pathogens Frequently Causing Community-Acquired Respiratory Tract Infections in Patients from a Global Population: ATLAS Surveillance Program 2018-2021
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2128)
In Vitro
Activity of Ceftibuten-Avibactam and Comparator Agents Against Resistant Enterobacterales from UTIs Collected Globally as Part of the ATLAS Surveillance Program, 2022
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2129) Antimicrobial Activity of Cefepime in Combination with Taniborbactam Against Resistant Clinical Isolates from the United States 2018-2021
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2149)
In vitro
Activity of Aztreonam-avibactam and Comparator Agents Against Carbapenem-Resistant Enterobacterales With and Without Carbapenemases, ATLAS Global Surveillance Program, 2017–2021
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2150)
In Vitro
Activity of Cefepime-Taniborbactam and Comparators Against Genotypically Characterized Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant
Pseudomonas aeruginosa
(CRPA) from the United States, 2018-2021
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2151)
In Vitro
Activity of Ceftazidime-Avibactam and Comparator Agents Against
Pseudomonas aeruginosa
Collected from Patients with Presumed Hospital- and Community-Acquired Respiratory Tract Infections: ATLAS Global Surveillance Program, 2017-2021
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2152) Activity of Imipenem/Relebactam Against Carbapenem-Resistant Non-
Morganellaceae
Enterobacterales (NME) in the United States – SMART 2019-2021
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2153) Addition of Relebactam Increases Susceptibility to Imipenem Alone against Class C β-lactamase-Positive Enterobacterales: Asia/Pacific SMART 2019-2021
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2154) Cross-resistance of Ceftolozane-Tazobactam and Imipenem-Relebactam Against Clinical
P. aeruginosa
Isolates from Bloodstream and Respiratory Tract Infections– SMART United States 2019-2021
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
(2155) Low prevalence of OXA-48-like carbapenemases and susceptibility to imipenem/relebactam among carbapenem-resistant non-
Morganellaceae
Enterobacterales isolates from Latin America – SMART 2018-2021
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET